Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent

Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent

LASSBio-1920 was synthesized due to the poor solubility of its natural precursor, combretastatin A4 (CA4). The cytotoxic potential of the compound against human colorectal cancer cells (HCT-116) and non-small cell lung cancer cells (PC-9) was evaluated, yielding IC<sub>50</sub> values of...

Full description

Bibliographic Details
Main Authors: Celina de Jesus Guimarães, Teiliane Rodrigues Carneiro, Marisa Jadna Silva Frederico, Guilherme G. C. de Carvalho, Matthew Little, Valder N. Freire, Victor L. B. França, Daniel Nascimento do Amaral, Jéssica de Siqueira Guedes, Eliezer J. Barreiro, Lídia Moreira Lima, Francisco W. A. Barros-Nepomuceno, Claudia Pessoa
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Pharmaceutics
Subjects:
combretastatin
PAMPA
pharmacokinetic
EGFR binding
tubulin
Online Access:https://www.mdpi.com/1999-4923/15/4/1282

Internet

https://www.mdpi.com/1999-4923/15/4/1282

Similar Items